For decades, lung disease has been the most visible and life-threatening part of cystic fibrosis. People might picture chronic (long-term) cough, breathlessness, recurrent chest infections and oxygen ...

Researchers have mapped how lung damage begins early in life for children with cystic fibrosis, providing new insights that will help reshape future care. The research team, led by Murdoch Children's ...

Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in etiology, share a common trajectory of irreversible lung scarring and functional ...

Nerandomilast, a PDE4B inhibitor, is now FDA-approved for progressive pulmonary fibrosis, offering immunomodulatory and antifibrotic effects. The FIBRONEER-ILD trial showed nerandomilast significantly ...

If you have idiopathic pulmonary fibrosis (IPF), a chronic lung condition that can cause shortness of breath, low oxygen levels in the blood, and scarring on the lungs (fibrosis), it’s important to ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical ...

Last year, Houghton Hutcheson, now 79, started experiencing shortness of breath on a trip to Colorado. When he returned, he scheduled a visit with his primary care physician, Eric Thomas, MD, MPH, ...

A new research paper was published in Volume 17, Issue 8 of Aging-US on August 8, 2025, titled "AI-driven toolset for IPF and aging research associates lung fibrosis with accelerated aging." In this ...